Nyrada Inc (AU:NYR) — Market Cap & Net Worth
Market Cap & Net Worth: Nyrada Inc (NYR)
Nyrada Inc (AU:NYR) has a market capitalization of $126.52 Million (AU$178.81 Million) as of September 21, 2026. Listed on the AU stock exchange, this Australia-based company holds position #18402 globally and #577 in its home market, demonstrating a 1.39% increase in market value over the past year.
Market capitalization, also known as net worth in stock markets, is calculated by multiplying Nyrada Inc's stock price AU$0.73 by its total outstanding shares 244949705 (244.95 Million). Also see NYR total assets for a full breakdown of the balance sheet.
Nyrada Inc Market Cap History: 2020 to 2026
Nyrada Inc's market capitalization history from 2020 to 2026. Data shows growth from $41.60 Million to $126.52 Million (18.50% CAGR). Also see cash flow conversion of Nyrada Inc for how efficiently the company converts equity into cash flow.
Nyrada Inc Market Cap to Earnings & Revenue Ratios Timeline
This chart shows how Nyrada Inc's valuation ratios have evolved. The Price to Sales (P/S) ratio compares market cap to revenue, while the Price to Earnings (P/E) ratio compares market cap to net income. Lower values may indicate a more undervalued company relative to its financial performance. Check current stock price of Nyrada Inc for real-time trading data and today's change.
Latest Price to Sales (P/S) Ratio
80.99x
Nyrada Inc's market cap is 80.99 times its annual revenue
Latest Price to Earnings (P/E) Ratio
N/A
P/E ratio not applicable due to negative or zero earnings
What These Ratios Tell Investors:
- Price to Sales (P/S) Ratio: Shows how much investors are paying for each dollar of the company's sales. Lower P/S ratios may indicate undervaluation.
- Price to Earnings (P/E) Ratio: Shows how much investors are paying for each dollar of the company's earnings. This is one of the most common valuation metrics.
- Trends in these ratios over time can indicate changing investor sentiment about the company's future growth prospects.
- Industry comparison provides context for whether the company is valued higher or lower than peers.
| Year | Market Cap (USD) | Revenue (USD) | Net Income (USD) | P/S Ratio | P/E Ratio |
|---|---|---|---|---|---|
| 2020 | $41.60 Million | $1.13 Million | -$5.77 Million | 36.96x | N/A |
| 2021 | $41.60 Million | $2.34 Million | -$3.53 Million | 17.81x | N/A |
| 2022 | $25.13 Million | $1.09 Million | -$3.97 Million | 22.98x | N/A |
| 2023 | $3.81 Million | $1.43 Million | -$7.82 Million | 2.67x | N/A |
| 2024 | $16.29 Million | $3.24 Million | -$1.39 Million | 5.03x | N/A |
| 2025 | $194.12 Million | $2.40 Million | -$4.85 Million | 80.99x | N/A |
Competitor Companies of NYR by Market Capitalization
Companies near Nyrada Inc in the global market cap rankings as of September 21, 2026. Review NYR tangible net worth ratio to assess the quality of the company's equity after excluding intangible assets.
Key companies related to Nyrada Inc by market ranking:
- Vertex Pharmaceuticals Inc (NASDAQ:VRTX): Ranked #189 globally with a market cap of $128.84 Billion USD.
- Regeneron Pharmaceuticals Inc (NASDAQ:REGN): Ranked #340 globally with a market cap of $79.38 Billion USD.
- CSL Ltd (AU:CSL): Ranked #459 globally with a market cap of $60.28 Billion USD ( AU$85.19 Billion AUD).
- Moderna Inc (NASDAQ:MRNA): Ranked #505 globally with a market cap of $54.14 Billion USD.
| Rank | Company | Symbol | Market Cap | Price |
|---|---|---|---|---|
| #189 | Vertex Pharmaceuticals Inc | NASDAQ:VRTX | $128.84 Billion | $508.34 |
| #340 | Regeneron Pharmaceuticals Inc | NASDAQ:REGN | $79.38 Billion | $784.85 |
| #459 | CSL Ltd | AU:CSL | $60.28 Billion | AU$175.59 |
| #505 | Moderna Inc | NASDAQ:MRNA | $54.14 Billion | $154.04 |
Nyrada Inc Historical Marketcap From 2020 to 2026
Between 2020 and today, Nyrada Inc's market cap moved from $41.60 Million to $ 126.52 Million, with a yearly change of 18.50%.
| Year | Market Cap | Change (%) |
|---|---|---|
| 2026 | AU$126.52 Million | -34.82% |
| 2025 | AU$194.12 Million | +1091.49% |
| 2024 | AU$16.29 Million | +327.27% |
| 2023 | AU$3.81 Million | -84.83% |
| 2022 | AU$25.13 Million | -39.58% |
| 2021 | AU$41.60 Million | 0.00% |
| 2020 | AU$41.60 Million | -- |
End of Day Market Cap According to Different Sources
On Sep 20th, 2026 the market cap of Nyrada Inc was reported to be:
| Source | Market Cap |
|---|---|
| Yahoo Finance | $126.52 Million USD |
| MoneyControl | $126.52 Million USD |
| MarketWatch | $126.52 Million USD |
| marketcap.company | $126.52 Million USD |
| Reuters | $126.52 Million USD |
Market cap values may vary slightly between sources due to differences in calculation methods, timing, and data refresh rates.
About Nyrada Inc
Nyrada Inc., a pre-clinical stage drug development company, engages in the development of small molecule drugs for cardiovascular and neurological diseases. Its lead candidate is Xolatryp, a small molecule drug which has completed phase 1 clinical trial for neuroprotection and cardioprotection indications and in patients with traumatic brain injury and ischaemic stroke. Nyrada Inc. was incorporat… Read more